Heart Failure
Conditions
Keywords
Severe heart failure, Growth hormone, exercise capacity, quality of life, cardiac function
Brief summary
Prospective randomized, placebo controlled, clinical trial to evaluate the effect of human growth hormone supplementation compared with placebo to patients with severe heart failure for a duration of 6 months on exercise capacity, heart function and quality of life
Interventions
Sponsors
Hamilton Health Sciences Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Individuals with a diagnosis of CHF, NYHA functional class III or IV symptoms, an EF of \< 35 % estimated on radionuclide angiography (RNA) or 2D echo within the last 6 months, and a 6 minute walk distance of less than 400 meters. Patients must be stabilized on CHF therapy at the time of randomization.
Exclusion criteria
1. Exercise limited by claudication, angina, neurological, pulmonary (FEV1 \< 50%; FVC \< 50%), or musculoskeletal disease. 2. Active known malignancy; remission of \< 5 years from the diagnosis of malignancy; patients with recurrence of malignancy are to be withdrawn from the study. 3. Current diabetes with known retinopathy or patients with poorly controlled diabetes (ie. fasting glucose more than 13 mmol/l) or Type I diabetes mellitus. 4. Any other non-cardiac condition that substantially decreases survival. 5. Significant valvular stenosis or hypertrophic cardiomyopathy. 6. Unable to comply with GH injection. 7. Pregnancy or women of child bearing age not using adequate contraceptive means. 8. Unstable angina, acute myocardial infarct, cardiac surgery, or PTCA within 3 months. 9. Cor pulmonale. 10. Acute myocarditis. 11. Known need for cardiac surgery (e.g., valvular intervention, or CABG, or PTCA) within the next 6 months. 12. Clinical hypothyroidism or hyperthyroidism with biochemical corroboration (TSH \> 7 or \< 0.2) at screening. 13. Patients in need of urgent heart transplant within the next 6 months (patients on transplant list remain eligible). 14. Sustained ventricular tachycardia (lasting \> 30 seconds) on screening Holter. 15. Significant liver disease (INR\>1.4 off anticoagulant therapy; or AST, or ALT, or GGT, or alkaline phosphatase \> 3X upper limit of normal; or bilirubin \> 2X the upper limit of normal) at baseline. 16. Failure to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-minute walk test distance (functional capacity)measured at baseline, 3 months, and 6 months from the start of the study. Also measured at 3 months following discontinuation of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac Function measured with radionuclide angiography and echocardiography | — |
| Exercise capacity measured during treadmill testing (duration of exercise) | — |
| Quality of life measured with Minnesota Living with Heart Failure | — |
| Neurohormones | — |
| baseline, 3 months, and 6 months from the start of the study. Also measured at 3 months following discontinuation of therapy | — |
Countries
Canada
Outcome results
None listed